Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Drops By 20.7%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 227,623 shares, a decline of 20.7% from the February 12th total of 287,071 shares. Currently, 1.4% of the company’s shares are short sold. Based on an average daily volume of 138,739 shares, the days-to-cover ratio is presently 1.6 days. Based on an average daily volume of 138,739 shares, the days-to-cover ratio is presently 1.6 days. Currently, 1.4% of the company’s shares are short sold.

Allarity Therapeutics Trading Down 6.7%

NASDAQ ALLR opened at $1.26 on Friday. Allarity Therapeutics has a 12 month low of $0.61 and a 12 month high of $2.35. The stock has a 50-day simple moving average of $1.06 and a 200 day simple moving average of $1.26. The company has a market capitalization of $20.26 million, a PE ratio of -2.14 and a beta of 0.20.

Institutional Trading of Allarity Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Private Advisor Group LLC acquired a new stake in shares of Allarity Therapeutics in the 3rd quarter valued at approximately $441,000. Renaissance Technologies LLC grew its holdings in Allarity Therapeutics by 274.1% during the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock valued at $267,000 after purchasing an additional 181,426 shares during the period. Citadel Advisors LLC acquired a new position in Allarity Therapeutics during the third quarter valued at approximately $149,000. DRW Securities LLC bought a new stake in Allarity Therapeutics in the fourth quarter valued at approximately $133,000. Finally, XTX Topco Ltd acquired a new stake in Allarity Therapeutics in the second quarter worth $51,000. 11.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ALLR has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, January 21st. Ascendiant Capital Markets increased their price objective on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.